Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Cash from Financing Activities of $4.4 million for Q1 2026, down 78.58% year-over-year from $20.6 million in Q1 2025, and up 570.15% quarter-over-quarter from $660000.0 in Q4 2025.
Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 78.58% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $86.4 million (up 284.02% YoY), while the FY2025 annual figure was $102.6 million, up 22.76% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $4.4 million, up from $660000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $81.7 million in Q1 2024, with the low at -$9.2 million in Q1 2023.
- The 5-year median for Cash from Financing Activities is $1.7 million (2024), against an average of $12.1 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 809.17% in 2023, then surged 478988.24% in 2025.
- Aquestive Therapeutics' Cash from Financing Activities stood at $234000.0 in 2022, then jumped by 1572.22% to $3.9 million in 2023, then sank by 95.99% to $157000.0 in 2024, then jumped by 320.38% to $660000.0 in 2025, then soared by 570.15% to $4.4 million in 2026.
- Business Quant data shows AQST's Cash from Financing Activities at $4.4 million in Q1 2026, $660000.0 in Q4 2025, and $81.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | -2.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.59 Mn |
| Jun 30, 2026 | -2.59 Mn |
| Mar 31, 2026 | 4.42 Mn |
| Mar 31, 2026 | 4.42 Mn |
| Dec 31, 2025 | 660,000.00 |
| Dec 31, 2025 | 660,000.00 |
| Sep 30, 2025 | 81.41 Mn |
| Sep 30, 2025 | 81.41 Mn |
| Jun 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -100,000.00 |
| Mar 31, 2025 | 20.65 Mn |
| Mar 31, 2025 | 20.65 Mn |
| Dec 31, 2024 | 157,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | -17,000.00 |
| Sep 30, 2024 | -17,000.00 |
| Jun 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 81.74 Mn |
| Mar 31, 2024 | 81.74 Mn |